First Tracks Biotherapeutics (NASDAQ:TRAX – Get Free Report) issued its earnings results on Wednesday. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.74) by ($0.21), Zacks reports.
First Tracks Biotherapeutics Stock Down 2.1%
Shares of TRAX stock traded down $0.99 during trading hours on Thursday, reaching $45.14. The company’s stock had a trading volume of 140,084 shares, compared to its average volume of 633,717. First Tracks Biotherapeutics has a fifty-two week low of $14.72 and a fifty-two week high of $49.91. The company’s 50 day moving average is $29.33. The firm has a market capitalization of $1.57 billion and a P/E ratio of -24.70.
Wall Street Analyst Weigh In
A number of research analysts recently issued reports on TRAX shares. Wall Street Zen upgraded shares of First Tracks Biotherapeutics to a “hold” rating in a report on Saturday, May 2nd. HC Wainwright upped their price objective on shares of First Tracks Biotherapeutics from $44.00 to $57.00 and gave the company a “buy” rating in a research report on Thursday. Wedbush raised their price objective on First Tracks Biotherapeutics from $60.00 to $70.00 and gave the stock an “outperform” rating in a research note on Thursday. Wells Fargo & Company boosted their target price on First Tracks Biotherapeutics from $30.00 to $55.00 and gave the company an “overweight” rating in a research note on Tuesday, July 28th. Finally, UBS Group raised their price target on First Tracks Biotherapeutics from $45.00 to $65.00 and gave the stock a “buy” rating in a research report on Monday. Eight analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, First Tracks Biotherapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $60.50.
About First Tracks Biotherapeutics
First Tracks Biotherapeutics is a clinical stage biotechnology company advancing antibody therapies which modulate immune pathways implicated in autoimmune and inflammatory diseases. Its pipeline includes ANB033 and ANB101. First Tracks Biotherapeutics is based in SAN DIEGO.
Featured Stories
- Five stocks we like better than First Tracks Biotherapeutics
- Axos Financial Keeps Proving the Digital Banking Model Works
- SpaceX’s First Earnings Report Only Made Wall Street More Divided
- Plug Power Charges Ahead: Margin Expansion Sparks a Rally
- Abercrombie’s Comeback Is a Work in Progress
Receive News & Ratings for First Tracks Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for First Tracks Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
